Potassium binders
Potassium binders are oral agents, patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate, that exchange gastrointestinal potassium for another cation and increase fecal potassium excretion. They treat sustained or chronic hyperkalemia, most often to permit continued renin-angiotensin-aldosterone system inhibitor therapy, and are not for emergent stabilization; patiromer and sodium zirconium cyclosilicate are the preferred agents.
- Topic reviewThe full article, organized the way the exam asks it.
- ABIM-format MCQsVignettes with an explanation for every wrong answer.
- Key factsThe numbers and thresholds worth memorizing, up front.
- AI tutorMedBrain answers the question you're stuck on.
What this article covers
- Overview
What they are: patiromer, sodium zirconium cyclosilicate (SZC), and sodium polystyrene sulfonate (SPS) are oral, non-absorbed compounds that bind potassium in the gut in exchange for another cation and carry it out in stool.
- Epidemiology
Who needs one: patients with CKD, diabetic kidney disease, or heart failure with reduced ejection fraction on an ACE inhibitor, angiotensin receptor blocker, or MRA for its mortality benefit.
- Risk factors
Reduced GFR: hyperkalemia becomes common once GFR falls below about 20 mL/min/1.73 m2, and oliguria in acute or chronic kidney disease sharply limits excretion further.
- Pathophysiology
Shared mechanism: all three binders are large, non-absorbed molecules that pass through the gut, capture potassium along their length, and are eliminated in stool.
- Clinical features
No independent symptoms: the picture being managed is hyperkalemia itself, muscle weakness and ECG change, not a syndrome the binder produces.
- Differential diagnosis
Insulin plus dextrose: shifts potassium into cells within minutes but does not remove it; effect wears off by about 6 hours, unlike a binder's sustained action.
- Diagnosis
What establishes the indication: a binder is indicated once a confirmed, non-hemolyzed serum potassium above 5.0 mEq/L is sustained or recurrent, most often in a patient who needs a RAAS inhibitor or MRA continued for its mortality benefit.
- Management
First, exclude an emergent indication: a potassium above 6.5 mEq/L, or above 6.0 mEq/L with ECG changes, needs intravenous calcium gluconate, then insulin with dextrose and nebulized albuterol; a…
- Complications
Hypomagnesemia: the most specific effect of patiromer; check magnesium periodically and replete if low.
- Prognosis
Effective maintenance therapy: both patiromer and SZC reliably lower potassium and sustain it in range for as long as dosing continues.
- Prevention
Scheduled monitoring: recheck potassium about 1 week after starting or up-titrating a RAAS inhibitor, MRA, or binder, then every few months once stable, with periodic magnesium checks on patiromer.
Read the whole article
Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.
Related articles
- Hyperkalemia
Hyperkalemia is a serum potassium level above 5.0 mEq/L, most often from decreased kidney excretion, transcellular shifts, or excess intake, with levels above 6.0-6.5 mEq/L or any ECG change constituting a medical emergency from the risk of fatal arrhythmia. Treatment sequences cardiac membrane stabilization with calcium, transcellular potassium shifting with insulin/dextrose and albuterol, then definitive potassium removal with binders, diuretics, or dialysis.
- Chronic kidney disease
Chronic kidney disease is abnormal kidney structure or function present for more than 3 months, staged by the Kidney Disease: Improving Global Outcomes (KDIGO) system using estimated glomerular filtration rate and albuminuria, and managed with blood pressure control, renin-angiotensin blockade, an SGLT2 inhibitor, and correction of its metabolic complications.
- Heart failure
Heart failure is a clinical syndrome of impaired cardiac filling or ejection causing congestion and reduced perfusion, classified by ejection fraction. Diagnosis integrates symptoms, signs, natriuretic peptides, and echocardiography, and treatment of reduced-ejection-fraction disease is quadruple guideline-directed therapy, with device therapy and cause-specific management.
- Hypomagnesemia
Hypomagnesemia is a serum magnesium level below 1.7 mg/dL, most often caused by gastrointestinal losses, proton pump inhibitors, or renal magnesium wasting from diuretics and other drugs. It causes concurrent hypokalemia and hypocalcemia and can potentiate cardiac arrhythmias, and treatment is intravenous magnesium sulfate for significant symptoms or slow-release oral repletion for milder deficiency.
- Renal tubular acidosis
Renal tubular acidosis is a normal anion gap metabolic acidosis caused by impaired renal bicarbonate reabsorption (type 2, proximal) or impaired distal acid excretion (type 1, hypokalemic distal, or type 4, hyperkalemic distal from aldosterone deficiency or resistance). The urine anion gap, serum potassium, and urine pH distinguish the three types, which are treated respectively with alkali replacement plus a thiazide, potassium citrate, and correction of the underlying cause plus mineralocorticoid replacement when appropriate.